DDrare: Database of Drug Development for Rare Diseases

Searched query = "Idiopathic multicentric castleman disease", "Castleman disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Best Supportive Care (BSC); Bevacizumab; Bortezomib; CNTO 328; CNTO328; CX-4945 oral formulation; Cetuximab; Chimeric murine human anti-IL-6 monoclonal antibody; Cyclophosphamide; Dexamethason; Doxorubicin; Doxorubicin Hydrochloride; Etoposide; Filgrastim; Filgrastim (G-CSF); G-CSF; Hyaluronidase; Interferon-alpha; Liposomal Doxorubicin; Methotrexate; Nelfinavir; Other: Laboratory Biomarker Analysis; Other: Observation Only; Other: Pharmacological Study; Pomalidomide; Prednisone; Rituximab; Rituximab or Rituximab Hyaluronidase Human; RoActemra; SILTUXIMAB; Siltuximab; Sirolimus; Suramin; Temsirolimus; Thalidomide; Thalidomide, cyclophosphamide and prednisone; Tocilizumab; Tocilizumab [RoActemra/Actemra]; Valganciclovir; Valganciclovir (VGC); Valproic Acid; Valproic acid; Vincristine; Zidovudine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2071190029	25/05/2020	09/10/2019	Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial (SPIRIT Compliant)	Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial (SPIRIT Compliant)	idiopathic multicentric Castleman's disease Castleman's disease	Treatment: Sirolimus 2 mg po once/day. Control: Placebo given orally once daily	Kawakami Atsushi	NULL	Recruiting	>= 18age old	Not applicable	Both	20	Phase 2	Japan
2	NCT03933904 (ClinicalTrials.gov)	September 25, 2019	29/4/2019	Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease	A Phase II, Single-arm Open-label Multi-center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease	Castleman Disease;Castleman's Disease, Multicentric	Drug: Sirolimus	University of Pennsylvania	NULL	Recruiting	18 Years	80 Years	All	24	Phase 2	United States
3	NCT00092222 (ClinicalTrials.gov)	October 28, 2004	21/9/2004	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity	Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity	Lymphoproliferative Disorder;HHV-8;Malignancy;HIV	Drug: Etoposide;Drug: Interferon-alpha;Drug: Rituximab;Drug: Zidovudine;Drug: Liposomal Doxorubicin;Drug: Bortezomib;Drug: Valganciclovir;Drug: Doxorubicin;Drug: Vincristine;Drug: Cyclophosphamide;Drug: Filgrastim (G-CSF);Drug: Prednisone;Drug: Sirolimus;Other: Observation Only	National Cancer Institute (NCI)	NULL	Recruiting	12 Years	N/A	All	72	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

JPRN-jRCT2071190029

25/05/2020

09/10/2019

Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial (SPIRIT Compliant)

idiopathic multicentric Castleman's disease
Castleman's disease

Treatment: Sirolimus 2 mg po once/day.
Control: Placebo given orally once daily

Kawakami Atsushi

NULL

Recruiting

>= 18age old

Not applicable

Both

Phase 2

Japan

NCT03933904
(ClinicalTrials.gov)

September 25, 2019

29/4/2019

Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

A Phase II, Single-arm Open-label Multi-center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

Castleman Disease;Castleman's Disease, Multicentric

Drug: Sirolimus

University of Pennsylvania

NULL

Recruiting

18 Years

80 Years

All

Phase 2

United States

NCT00092222
(ClinicalTrials.gov)

October 28, 2004

21/9/2004

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity

Lymphoproliferative Disorder;HHV-8;Malignancy;HIV

Drug: Etoposide;Drug: Interferon-alpha;Drug: Rituximab;Drug: Zidovudine;Drug: Liposomal Doxorubicin;Drug: Bortezomib;Drug: Valganciclovir;Drug: Doxorubicin;Drug: Vincristine;Drug: Cyclophosphamide;Drug: Filgrastim (G-CSF);Drug: Prednisone;Drug: Sirolimus;Other: Observation Only

National Cancer Institute (NCI)

NULL

Recruiting

12 Years

N/A

All

Phase 2

United States